The RANKL-induced NF-κB signaling pathway is required for osteoclast formation and function. By screening for compounds that inhibit RANKL-induced NF-κB activation using a luciferase reporter gene assay in RAW264.7 cells, we identified triptolide (PG490), as a candidate compound targeting osteoclast differentiation and osteoclast-mediated osteolysis.
Introduction
Osteoclasts are multinucleated, terminally differentiated cells that are responsible for the degradation of mineralized bone matrix (Teitelbaum, 2000) . Osteoclasts differentiate from mononuclear cells of the monocyte and macrophage lineage through a process collectively known as osteoclastogenesis (Teitelbaum, 2000) . Pivotal to this process is the transcription factor nuclear factor kappa B (NF-κB), which plays an important role in both osteoclast differentiation and survival (Boyce et Prosthetic wear particles, such as polymethylmethacrylate and titanium particles are involved in the initiation and development of periprosthetic osteolysis that leads to irreversible aseptic loosening of prostheses (Goodman et al., 2006) . These particles can stimulate osteoclastmediated bone resorption (Goodman et al., 2006) , an action that can promote periprosthetic osteolysis in the bone microenvironment. In addition, both direct and indirect mechanisms of particle-induced osteolysis may involve exacerbated inflammation with the production of pro-inflammatory cytokines, impaired periprosthetic bone formation, and compromised bone regeneration (Wang et al., 2004) . To date, effective therapy against particle-induced osteolysis is limited to surgical revision. Identification of drugs that can inhibit particleinduced osteolysis therefore remains a major challenge in the treatment of particle-induced osteolysis.
Triptolide (C 20 H 24 O 6 ) is a highly oxygenated diterpene triepoxide and contains 9,11-epoxide and the 14β-oriented-hydroxyl system, which are necessary for the anti-leukaemic and immunosuppressive activity (Tao et al., 2001) . Triptolide is involved in antitumor activity against prostate cells (Kiviharju et al., 2002) , possesses significant therapeutic benefit for immunosuppression (Kusunoki et al., 2004) , has anti-inflammatory and anti-leukemia activity Lipsky, 2000,Tao et al., 2002) , and blocks the induction of NF-κB activity by TNF-α, through functioning as a NF-κB inhibitor. (Fidler et al., 2003) Previous studies have shown that triptolide inhibits NF-κB transcriptional activation triggered by phorbol 12-myristate 13-acetate (PMA), PMA/Iono and TNF-α stimuli via specific binding of the p50-p65 heterodimer to DNA (Qiu et al., 1999) . However, no data has been available in regards to whether triptolide exerts a therapeutic effect on particle-induced osteolysis, as well as on RANKL -mediated osteoclastogenesis and NF-B activation.
Through the biological screening for compounds that inhibit RANKL-induced NF-κB activation by a luciferase reporter gene assay in RAW264.7 cells, we identified Triptolide (PG490), as a candidate compound targeting osteoclasts and osteoclast-mediated osteolysis.
Our results demonstrate that triptolide suppresses osteoclastogenesis, bone resorption and RANKL-mediated NF-κB activation, and attenuates particle-induced osteolysis in vivo, suggesting that triptolide possesses therapeutic potential for the treatment of osteolysis.
Materials and Methods

Media and reagents
RAW264.7 cells were obtained from the American Type Culture Collection (Rockville, MD). α-Modification of Eagle's Medium (α-MEM) and fetal bovine serum (FBS) were purchased from TRACE (Sydney, NSW, Australia). L-glutamine, penicillin and streptomycin were purchased from Gibco BRL (Melbourne, Australia). Triptolide was purchased from Axxora Sapphire Bioscience Pty. Ltd. (AU-Redfern, NSW, Australia). Triptolide powder was dissolved in dimethyl sulfoxide (DMSO) and then diluted in phosphate buffered saline (PBS).
Natural compounds (with a purity ≥ 98%) were obtained from Professor Jun Xu of San Yatsen University, Professor Ren Xiang Tan of Nanjing University, Professor Jiming Ye RMIT University, Melbourne, or Chengdu MUST Bio-technology Co., LTD (China). All compounds were dissolved in dimethysulfulfoxide (DMSO) purchased from BDH laboratory supplies (Poole, Dorset, England). Recombinant GST-RANKL was prepared as previously described (Xu et al., 2000) .
Drug screening assay and NF-κB activity in RAW264.7 cells
Drug biological screening assays were conducted to evaluate RANKL-mediated NF-κB activity using RAW264.7 cells stably transfected with an NF-κB-driven luciferase reporter gene construct (3κB-Luc-SV40) with natural and synthetic compounds at concentrations of 1 to 10 µM. To investigate the effect of triptolide on RANKL-induced NF-κB activity, RAW264.7 cells stably transfected with an NF-κB-driven luciferase reporter gene construct (3κB-Luc-SV40) were treated with various doses of triptolide for 1 hour prior to the incubation with 100ng/ml RANKL for 8 hours. Luciferase activities were measured using a POLARstar Optima luminescence detection system (BMG Labtech) ).
Osteoclastogenesis assay
Primary bone marrow macrophages (BMM) isolated from C57BL/6 mice were seeded (1×10 
Bone resorption pit assay
To examine the effect of triptolide on osteoclastic-bone resorption, BMM derived osteoclasts cultured from collagen coated plates were cultured in α-MEM medium supplemented with 10% FBS and 100 IU/ml penicillin, 100 µg /ml streptomycin, 2.5 mg/ml amphotericin and 50 IU mycostatin at 37°C in a water saturated atmosphere with 5% CO 2 and fed by medium replacement every 2-3 days for a total of 5-7 days. Osteoclasts cultured in collagen coated plates were then washed once with PBS and treated for 20 minutes with 250µl of cell dissociation buffer (Sigma) per 25-mm-diameter well. The detached cells were pelleted and resuspended in 150µl of α-MEM, aliquoted onto 150µm thick dentine bone slices in wells of a 96 well plate, and incubated for 2 hours to ensure proper attachment of cells onto bone substrate before the addition of Triptolide. After cell attachment, the bone slices were treated either with Triptolide (5 nM) or left untreated. After 48 hours at 37°C incubation, the bone slices were fixed with 4% paraformaldehyde, osteoclasts were TRAP stained and counted, prior to treatment with 2M NaOH. Cells were removed by gentle brushing and sonication.
The resorption pits were visualized by a Philips XL30 scanning electron microscope (SEM).
The percentage of resorbed area on bone surface normalized to osteoclast number was 
Preparation of Titanium Particles
Commercial pure titanium particles, with a density of 4.507 g/cm3, were purchased from Alfa Aesar (Ward Hill, MA, USA). These particles were diluted with pure water and filtered by Millipore filter membranes (Billerica, MA, USA) of a series of sizes (pore diameter: 0.2, 1.2, and 10μm). Three ranges of particle size, 0.2-1.2 µm (TI-0.2), 1.2-10 µm (TI-1.2) and >10 µm (TI-10) were obtained after filtration. All particles were washed with 70% ethanol for 24 h at room temperature and then dried in a biological drying oven. The dried particles were sterilized with ethylene oxide. According to particle weight and density, the concentration of the particles suspended in PBS was adjusted to 4 × 10 8 mm 3 /mL. The level of endotoxin in particle solutions was measured using the limulus amebocyte lysate assay (QCl-1000; Bio Whittaker, Walkersville, MD, USA), and the results showed that the endotoxin level was under the detection level of 0.01 EU/mL. An image analysis system (NIKON, Tokyo, Japan) was used to confirm the exact size of the particles, which showed that there were no significant differences in size between different particles (data not shown).
Animal Surgery and Experimental Protocol
Twenty 11-week-old C57BL/6J male mice were purchased from Animal Laboratory of Sun
Yat-sen University (Guangzhou, Guangdong, China). All mice were handled in agreement with Chinese and international guidelines for care and use of laboratory animals. Animals were housed in quarantine under local vivarium conditions (24°C, 12h/12h light/dark cycle) for 1 week. The surgical procedures have been described previously. (Wedemeyer et al., 2007) Briefly, mice were operated under general anesthesia via intraperitoneal injection of chloral hydrate. All mice were 12 weeks of age at surgery. A 0.5 × 0.5 cm 2 area of periosteum was exposed by making a 10-mm midline sagittal incision over the calvaria. These mice were divided into 3 groups randomly. Each of five mice received local calvaria injection of 100 µl TI-0.2 particles; five mice received 100 µl TI-0.2 particles and 50 µl triptolide suspension (equivalent to 1mg/kg); five mice sham-operated with 100 µl PBS constituted the sham control. The incision was closed using nonabsorbable suture (Yangzhou Guo Tai Co., Ltd, China). The mice were returned to their cages after they were able to right themselves. Water and food were given ad libitum. No mice died during the experiments, and no wound complications were observed. Fourteen days postoperatively, the mice were euthanized, and the calvaria harvested for CT scan analysis and micro-CT imaging.
Micro-computed Tomography
The skulls were analyzed with a high-resolution micro-CT (µCT 80; Scanco Medical AG, Bruettisellen, Switzerland) to perform qualitative analyses of the calvarial bone. Micro-CT analysis focused on the osseous properties in the area of the sagittal suture of the skulls. The radiographic projections (n=500) were acquired at 55 kV and 145 µA with a fixed exposure time of 300 ms and all projection frames were recorded 6 times and then averaged. 3D
images were reconstructed with a voxel average size of 12 µm, using the manufacturer's reconstruction software (Scanco Medical AG).
Histology
Paraffin embedded sections (4 μm) were taken in the frontal plane centered over the area of particle-induced osteolysis and stained with Goldner dye. The Goldner-stained sections were analyzed by transmission light microscopy (Axiophot, Zeiss, Germany). The existence and dimension of granulomatous foreign body reaction and bone resorption were evaluated using a standard high-quality light microscope. Histomorphometric analysis was made by image analysis software (UTHSCA Image Tool, IT version 3.0; University of Texas, San Antonio, TX) as described previously (Wedemeyer et al., 2007 ) .
Statistical analyses
Data were presented as mean ± SEM. Student's t-test was used to determine statistical significance between groups. A p-value of < 0.05 was considered to be statistically significant.
Results
Triptolide inhibits osteoclastogenesis in vitro
Using a high-throughput luciferase reporter gene assay to screen a library of 120 compounds, consisting of natural compounds and their derivatives, for potential inhibitors of RANKLinduced activation of NF-κB, we identified triptolide (Fig. 1) , as a candidate compound that potently inhibited RANKL-induced NF-κB activation ( Table 1 ). Given that NF-κB activity is crucial to osteoclast formation and function, we first investigated the cellular and molecular basis of the inhibitory effects of triptolide on osteoclastogenesis in vitro using an established primary bone marrow macrophage (BMM) osteoclastogenic culture system. As shown in 
Triptolide inhibits osteoclastic bone resorption
Next, to examine the inhibitory effect of triptolide on osteoclastic bone resorption, a bone resorption pit assay was performed using BMM-derived osteoclasts. As shown in Figure 3A 
Triptolide suppresses RANKL-induced activation of NF-қB in osteoclast like cells
As aforementioned, the NF-қB pathway plays a crucial role in RANKL-induced osteoclastogenesis. Therefore, we next, investigated the effect of triptolide on NF-қB activity using RAW264.7 cells stably transfected with an NF-қB-driven luciferase reporter gene construct (3қB-Luc-SV40). As shown in Figure 4 , RANKL induced a significant increase in NF-қB activation compared to unstimulated RAW264.7 cells which served as a basal control.
Treatment with triptolide showed dose-dependent suppression of RANKL-stimulated NF-қB activation in RAW264.7 cells at concentrations of 0.62 nM, 1.25 nM and 2.5 nM (p < 0.001).
Triptolide suppresses RANKL-induced p65 nuclear translocation
To further explore the effect of triptolide on NF-κB activity, we evaluated the effect of triptolide on RANKL-mediated p65 nuclear translocation in BMMs. Figure 5 shows that treatment of BMMs with triptolide decreases the RANKL-induced cytosol-nuclear translocation of p65, as compared to vehicle control cells which possessed a higher percentage of cells displaying clear nuclear translation of p65. Anti-mouse IgG, which served as a negative control, showed negligible staining (Fig. 5 ).
Triptolide treatment reduced titanium particle-induced osteolysis of calvarial bone.
Next, we examined the effect of triptolide on titanium particle-induced osteolysis in vivo using our previously published procedures (Wedemeyer et al., 2007) . During the treatment, we did not observe weight loss and abnormal behavior of triptolide treated mice. Micro-CT analysis showed that administration of titanium particles to the surface of mouse calvarial bone elicits a localized inflammatory and osteolytic response which significantly widens the cranial suture width. By comparison, Sham-operated mice show no obvious signs of osteolytic activity. Importantly, treatment with triptolide significantly decreased the cranial suture width induced by titanium particles (Fig. 6 ).
To enable more detailed examination of the effects of triptolide on sagittal suture resorption area and osteoclast formation in vivo, we performed histological assessment of the calvaria. As shown in Figure 6C , titanium particles caused a significant increase in sagittal suture resorption area, whereas co-injection with triptolide significantly reduced titanium particle-induced sagittal suture resorption area. Taken together, these findings indicate that triptolide attenuates osteoclast-mediated osteolysis.
Discussion
In the present study, we addressed the therapeutic potential of triptolide as a candidate inhibitor of osteoclastogenesis, bone resorption, RANKL-induced NF-қB signaling pathways Many orthopaedic implants fail due to particle-stimulated aseptic loosening. To date, therapy against particle-induced osteolysis is limited to surgical revision. Thus, identification of drugs that can suppress particle-induced osteolysis will improve treatment options for particlestimulated aseptic loosening. In this study, we demonstrate that triptolide effectively suppressed titanium particle-induced osteolysis. Osteolysis induced by titanium particles is accompanied by increased numbers of osteoclasts locally in mice. Interestingly, we found that triptolide treatment reduced osteoclast formation in titanium particle-treated animals in vivo, and RANKL-mediated osteoclastogenesis in vitro, an action that has not been previously assigned to this compound. Based on our in vitro observations, it is likely that the direct inhibition of RANKL-induced osteoclastogenesis by triptolide largely accounts for the suppression of titanium particle-induced osteolysis observed in vivo.
Triptolide has also been shown to display a therapeutic effect on solid tumor, leukemia, and a variety of inflammatory disorders, which is often accompanied by increased osteoclast In summary, through biological screening of a compound library, we identified triptolide as a potent suppressor of osteoclast formation, bone resorption and RANKL-induced NF-қB activation in vitro, and titanium particle-induced osteolysis in vivo. Together, these results highlight the therapeutic potential of triptolide for treatment of bone lytic diseases.
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Triptolide inhibited osteoclastogenesis and bone resorption, and RANKL-induced NF-kB activities.
Triptolide attenuates titanium-induced osteolysis and osteoclast formation in a mouse calvarial model.
Triptolide might have therapeutic potential for the treatment of bone lytic diseases caused by prosthetic wear particles.
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